Novo Nordisk A/S NOVO-B.CO
Composite 62/100; the shares have moved about 35% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 44/100 — a slight mark against it.
Income ranks 86/100 — a strong point in its favour. Quality ranks 81/100 — a strong point in its favour. Balance-sheet strength ranks 61/100 — a slight point in its favour.
Growth ranks 44/100 — a slight mark against it.
What the company does Novo Nordisk A/S is a Danish drugmaker focused on diabetes, obesity, and rare diseases. Its GLP-1 therapies (e.g., Wegovy, Ozempic) drive revenue, while pipelines span obesity, cardiovascular, and rare blood disorders.
Key financials ROE 71.4%, ROA 19.2%, ROCE 48.1%. Margins: gross 83.2%, operating 61.6%, net 37.2%. Revenue/EPS growth: 24.0%/67.1%. Debt/equity 0.72x; interest coverage 7.36x.
Stock health 3m momentum 28.29%, 12m -20.10%. RSI(14) 65.00. Sideravia scores: Quality 84.7, Growth 65.5, Valuation 60.8, Income 84.6. Dividend yield 3.5%.
Price vs fair value The stock trades at a **PREMIUM** of 6.17% versus the 12-month analyst target of 317.20 and at a **discount** of 83.60% versus our fair-value estimate of 620.75. - Recent pipeline setbacks (Ziltivekimab cardiovascular trial failure) weighed on sentiment (MT Newswires, Barrons.com, GuruFocus.com). - Competitive pressure from Eli Lilly’s GLP-1 advances cited as a key headwind (Motley Fool, 24/7 Wall St.). - Analysts still rate valuation as fair despite premium to targets (Sideravia Valuation 60.8/100).
Looking forward Forward P/E 14.75; FCF yield -0.8%. Next catalyst: upcoming earnings and pipeline updates. Focus remains on GLP-1 dominance and rare disease expansion.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.